Phase 3 Study of Oral Ibrexafungerp (SCY-078) Vs. Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC)

NCT04029116 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

440

Enrollment

INDUSTRY

Sponsor class

Conditions

Recurrent Vulvovaginal Candidiasis

Interventions

DRUG: Fluconazole Tablet
DRUG: IBREXAFUNGERP
DRUG: Placebo oral tablet

Sponsor

Scynexis, Inc.